Qiagen NV (NYSE:QGEN)
$ 38.72 -0.43 (-1.1%) Market Cap: 7.99 Bil Enterprise Value: 8.99 Bil PE Ratio: 19.95 PB Ratio: 2.40 GF Score: 69/100

Qiagen NV at JPMorgan Healthcare Conference Transcript

Jan 12, 2026 / 07:15PM GMT
Release Date Price: $47.25 (-2.15%)
Casey Woodring
JPMorgan Chase & Co - Analyst

Great. Welcome to the JPMorgan Healthcare Conference, everybody. My name is Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Thierry Bernard, CEO of Qiagen.

This will be the standard 40-minute session. We'll do a corporate presentation, then Q&A afterwards. Thierry, all yours.

Thierry Bernard
Qiagen NV - Chief Executive Officer, Managing Director, Member of the Executive Board

Thank you so much, and good morning, everybody. A very happy new year. I do apologize that I'm standing between you and your lunch, but I think it's always better than presenting after lunch anyway.

So I'm very pleased to present and discuss with you the most recent progresses and achievement of Qiagen in '25. Qiagen, a company that continues to systematically deliver on our commitments not only for growth but also profitability, product development, but also a company that continues to invest to fuel that growth and enhance that performance.

You are probably aware

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot